Human haptocorrin in hepatocellular carcinoma
Human haptocorrin in hepatocellular carcinoma
复制标题
DOI：
10.1046/j.1525-1500.1999.09914.x
复制
发表时间：
1999-01-01
影响因子：
--
通讯作者：
Nicolas, JP
中科院分区：
文献类型：
--
作者：
Boisson, F;Fremont, S;Nicolas, JP
本研究的目的是确定是否haptocorrin（HC），维生素B-12的结合剂，是储存在肝细胞，以及是否这种储存是由肝癌发生的修改。使用免疫组织化学对不同的肝组织（正常肝和脂肪变性，N = 22; ci;肝硬化，N = 13;和肝细胞癌，N = 31）进行。无显着的HC免疫染色检测到非癌活检，在一个例外的情况下，肝硬化。肝细胞癌（HCC）切片显示癌细胞（93%的病例）和肿瘤周围的非癌肝细胞（95%）的弱至中度细胞质染色。具有假腺结构的切片显示其分泌产物的中度至强烈染色。这些结果和以前的研究似乎证实了这样的假设，即在HCC中观察到的HC血清水平升高是由于HC的肝脏合成增加和HCC患者血清中存在的该糖蛋白的特定亚型的肝脏摄取减少。
This study aimed to determine whether haptocorrin (HC), a vitamin B-12 binder, is stored in hepatic cells and whether this storage is modified by hepatic carcinogenesis. It was carried out using immunohistochemistry on different liver tissues (normal liver and steatosis, N = 22; ci;cirrhosis, N = 13; and hepatocellular carcinoma, N = 31). No significant immunostaining of HC was detected in noncancerous biopsies with the exception of in one case of cirrhosis. Hepatocellular carcinoma (HCC) sections showed a weak to moderate cytoplasmic staining of cancerous cells (93% of cases) and of noncancerous hepatocytes surrounding the tumor (95%) of cases. Sections with pseudoglandular structures showed a moderate to strong staining of their secretion products. These results and previous studies would seem to confirm the hypothesis that the raised HC serum level observed in HCC is due both to the increased hepatic synthesis of HC and to a decreased uptake by the liver of the particular isoform of this glycoprotein present in the serum of HCC patients.